Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics names Jeffrey Hessekiel EVP, Chief Legal and Administrative Officer

Neutral Impact 3 of 5 leadership Written later

Cytokinetics said it hired Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, effective November 14, 2025, under an offer letter dated November 13, 2025. He most recently served as Executive Vice President and General Counsel of Exelixis, Inc. The filing sets out a $660,000 base salary, a $400,000 signing bonus, and a $5.8 million initial restricted stock unit award, which gives the role a defined pay structure for shareholders to track.

Key points

  • Start date: November 14, 2025; base salary initially $660,000
  • Target annual bonus 50% of base salary, with 75% tied to corporate goals
  • Signing bonus of $400,000, partly subject to repayment if he leaves within one year
  • Initial RSU award with a grant date value of $5,800,000, vesting 40%, 40% and 20% over three years

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECNov 14, 2025, 4:05 PM ET
Accession number0001193125-25-282889

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 14, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.